DR VENOOK: TML, I think, stood for treatment of multiple lines. So about 820 patients were randomly assigned, at the time of progression, to either receive an alternative chemotherapy, so a flip between an oxaliplatin-based regimen to an irinotecan-based regimen or vice-versa, with or without the continuation of bevacizumab.
These were selected patients, so these were not patients who were primarily refractory. They had to have tolerated bevacizumab, had to have had it at least for 3 months. And so these are the patients who do well, who have already proven that they don’t have major issues with bevacizumab.
And the results very clearly showed that in the patients who continued on bev as opposed to those who received just the alternative chemotherapy, the survival was improved by 1.4 months, as Rich said.
There is a putative biomarker for bevacizumab, a paper a JCO a few weeks ago, looking at VEGF-A, circulating VEGF-A with a new assay, a different assay than has been used in the past. In a few diseases it does really suggest that this may be a biomarker.
This is an assay that looks at different isoforms and favors short isoforms versus the longer isoforms. So I believe they will be doing that analysis in this study. And you would hope that this might be another place where you could see who benefited and who didn’t.